Trade SGTX

Sigilon Therapeutics, Inc.

-

00:00:00

Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read more...

SGTX
Trading Specifications

Digits

3

Point

0.001

Spread

 
floating

Contract Size

1

Volume Min

1

Volume Max

10,000

Volume Step

1

Swap Long (Points)

 
-0.140

Swap Short (Points)

-0.080
Available on
MT5, TV, cTrader
Last update at May 20, 13:01 GMT+3
*Data Source: MT5 Server Prime Account Pricing

1D Change

0%

Why BlackBull Markets?

26k+

Tradable Assets

1:500

Leverage up to

Regulated

Multi-Regulated

24/7

Customer Support

$0

No Minimum Deposit

Margin Calculator

Calculation Results

Current Price

22.60

Required Margin

Converted Currency

Required Margin

Account Base Currency

Profit/Loss Calculator

PIP Value:

Stop loss in PIPs

Stop loss at:

Take profit in PIPs

Take profit at:

Swaps Calculator

Join Now